USA - engelsk - NLM (National Library of Medicine)

conversion labs pr, llc - minoxidil (unii: 5965120sh1) (minoxidil - unii:5965120sh1) - use to regrow hair on the scalp hair regrowth treatment do not use if: your degree of hair loss is different than shown on the side of this carton, because this product may not work for you you have no family history of hair loss your hair loss is sudden and/or patchy your hair loss is associated with childbirth you do not know the reason for your hair loss you are under 18 years of age. do not use on babies or children your scalp is red, inflamed, infected, irritated, or painful you use other medicines on the scalp stop use and ask a doctor if - chest pain, rapid heart beat, faintness, or dissiness occurs - sudden, unexplained weight gain occurs - your hands of feet swell - scalp irritation or redness occurs - you do not see hair regrowth in 8 months

USA - engelsk - NLM (National Library of Medicine)

conversion labs pr, llc - minoxidil (unii: 5965120sh1) (minoxidil - unii:5965120sh1) - hair regrowth treatment for men use to regrow hair on the top of the scalp (vertex only, see pictures on side of carton) do not use if: - you are a woman - your amount of hair loss is different than shown on the side of this carton or hair loss is on the front of the scalp, 5% minoxidil topical solution is not intended for frontal baldness or receding hairline - you have no family history of hair loss - your hair loss is sudden and/or patchy - you do not know the reason for your hair loss - you are under 18 years of age. do not use on babies or children - your scalp is red, inflamed, infected, irritated, or painful - you use other medicines on the scalp stop use and ask a doctor if - chest pain, rapid heart beat, faintness, or dissiness occurs - sudden, unexplained weight gain occurs - your hands or feet swell - scalp irritation or redness occurs - you get unwanted facial hair growth - you do not see hair regrowth in 4 months

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: silicified microcrystalline cellulose; maize starch; croscarmellose sodium; magnesium stearate - flecainide mlabs is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide mlabs should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide mlabs tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; silicified microcrystalline cellulose - flecainide mlabs is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide mlabs should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide mlabs tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

micro labs gmbh - acétate de flécaïnide - comprimé - 100,0 mg - composition pour un comprimé > acétate de flécaïnide : 100,0 mg - antiarythmiques, classe ic

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

micro labs gmbh - acétate de flécaïnide - comprimé - 50,0 mg - composition pour un comprimé > acétate de flécaïnide : 50,0 mg - antiarythmiques, classe ic

Canada - fransk - Health Canada

hoffmann-la roche limited - mofétilmycophénolate (chlorhydrate de mofétilmycophénolate) - poudre pour solution - 500mg - mofétilmycophénolate (chlorhydrate de mofétilmycophénolate) 500mg - immunosuppressive agents

Canada - fransk - Health Canada

hoffmann-la roche limited - mofétilmycophénolate - poudre pour suspension - 200mg - mofétilmycophénolate 200mg - immunosuppressive agents

Canada - fransk - Health Canada

hoffmann-la roche limited - mofétilmycophénolate - capsule - 250mg - mofétilmycophénolate 250mg - immunosuppressive agents

Canada - fransk - Health Canada

hoffmann-la roche limited - mofétilmycophénolate - comprimé - 500mg - mofétilmycophénolate 500mg - immunosuppressive agents